argenx - ARGX Stock Forecast, Price & News

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ARGX shares. HC Wainwright raised their price target on argenx from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Friday, July 29th. Morgan Stanley lifted their price target on shares of argenx from $375.00 to $401.00 and gave the company an "overweight" rating in a research note on Friday, July 29th. Piper Sandler upped their price target on shares of argenx from $415.00 to $425.00 and gave the company an "overweight" rating in a report on Monday, July 25th. SVB Leerink raised their price objective on shares of argenx from $404.00 to $428.00 and gave the stock an "outperform" rating in a report on Friday, July 29th. Finally, Deutsche Bank Aktiengesellschaft raised shares of argenx from a "hold" rating to a "buy" rating in a research note on Friday, May 13th. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $395.00.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $376.91 on Monday. The stock has a market capitalization of $20.75 billion, a PE ratio of -21.75 and a beta of 0.84. argenx has a 52 week low of $249.50 and a 52 week high of $387.89. The stock has a 50 day moving average price of $359.23 and a 200 day moving average price of $321.22.